Hence, after introducing the importance of the TME in breast cancer and the CCL5/CCR5 axis with its up- and downstream pathways, we highlight the main barriers and hurdles for the clinical adoption of anti-CCR5 therapy in breast cancer. Here, CCR5 is linked to breast cancer.